Lymphoma is a cancer of the lymphatic system—the network of vessels and glands that help your body fight infection. When cells in the lymph nodes or other lymphoid tissues grow abnormally, a lymphoma diagnosis follows. But "lymphoma" isn't one disease. There are dozens of subtypes, and understanding the major categories helps you grasp what your doctor is describing and what questions to ask next.
The first major split is between Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). This distinction matters because it affects staging, treatment options, and how doctors monitor your response to therapy.
Hodgkin lymphoma is defined by the presence of specific abnormal cells called Reed-Sternberg cells. It tends to spread in an orderly pattern from one lymph node group to adjacent groups. It accounts for a smaller share of all lymphoma diagnoses, but historically has had some of the most established treatment pathways.
Non-Hodgkin lymphoma is everything else—a much larger umbrella covering many subtypes. It doesn't follow the same orderly spread pattern and is more likely to skip around, appearing in multiple, distant locations at once.
NHL lymphomas are often divided by how fast they grow—a factor that shapes both prognosis and treatment urgency.
Indolent (slow-growing) lymphomas like follicular lymphoma or marginal zone lymphoma grow slowly and may not require immediate treatment. Some people live for years without therapy, though the disease typically cannot be cured with current standard treatments. The tradeoff: slower progression, but fewer long-term remission options.
Aggressive (fast-growing) lymphomas like diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma require prompt treatment but often respond well to chemotherapy or newer approaches. The potential upside is a higher chance of long-term remission or cure, especially if caught early.
In between sits a gray zone of intermediate-grade lymphomas, where behavior and optimal timing vary.
Beyond growth rate, your doctor will identify:
| Subtype | Growth Rate | Key Notes |
|---|---|---|
| Follicular lymphoma | Indolent | Most common indolent NHL; often stage 3–4 at diagnosis |
| Diffuse large B-cell lymphoma (DLBCL) | Aggressive | Most common aggressive NHL; potentially curable with intensive chemotherapy |
| Marginal zone lymphoma | Indolent | Often linked to chronic immune stimulation; may arise in stomach lining |
| Lymphoplasmacytic lymphoma | Indolent | Often associated with Waldenström macroglobulinemia |
| Mantle cell lymphoma | Intermediate to aggressive | Historically challenging; newer treatments expanding options |
| Burkitt lymphoma | Aggressive | Rare but fast-growing; requires urgent, intensive treatment |
| T-cell lymphomas | Variable | Less common; behavior and treatment vary widely by subtype |
Your specific lymphoma subtype influences:
Getting a precise diagnosis—not just "lymphoma," but the specific subtype, stage, and any relevant genetic markers—is your foundation. Your pathology report should specify the cell type, growth rate category, and any mutations tested. If those details aren't clear, ask your doctor to walk you through them.
The lymphoma landscape is complex, but your medical team uses these distinctions every day to tailor treatment to your specific disease. Understanding the framework helps you ask better questions and participate more fully in decisions about your care.
